In one single-arm Phase II study, 16 patients harboring an EGFR-mutant NSCLC with four or fewer distant metastases were treated with 3 months of an EGFR inhibitor, followed by SBRT directed to all sites of disease [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.